Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant gemcitabine + nab-paclitaxel for resectable pancreatic cancer
ACTRN12611000848909Phase 2Completed
- Sponsor
- Australasian Gastro-Intestinal Trials Group
- Start
- Jun 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of gemcitabine and paclitaxel in pancreatic cancer (PC) and pancreatic adenocarcinoma (PDAC), sponsored by Australasian Gastro-Intestinal Trials Group. Started Jun 2013; status: completed.
02
Drugs
gemcitabinepaclitaxel
03
Conditions
pancreatic cancer (PC)pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on ACTRN12611000848909.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12611000848909.